Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

RELATED NEWS
Trade MRK now with 

Merck (MRK: Quote) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast. Stocks fluctuated over the course of the trading day on Wednesday before ending the session mostly higher. The Dow and the S&P 500 both finished the day in positive territory, although the tech-heavy Nasdaq posted a modest loss. President Barack Obama spoke harshly of the terrorist group allegedly responsible for the execution of American freelance journalist James Foley in a statement on Wednesday. Obama described the group known as the Islamic State of Iraq and the Levant, or ISIL, as a cancer that needs to be extracted.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.